Latest & greatest articles for measles

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on measles or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on measles and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for measles

1. What is the role of serologic testing for immunity to measles during an outbreak?

What is the role of serologic testing for immunity to measles during an outbreak? What Is The Role Of Serologic Testing For Immunity To Measles During An Outbreak? – Clinical Correlations Search What Is The Role Of Serologic Testing For Immunity To Measles During An Outbreak? September 18, 2019 6 min read By Sandra Goldlust Peer Reviewed Measles was declared eliminated from the US in 2000. Our country, however, is currently in the midst of the largest measles outbreak since 1992. As of July (...) preschool closures for failure to comply with , 5 and controversial bans on unvaccinated children from entering schools, . 6 Measles is a highly transmissible virus with a basic reproductive number (R 0 ) of 12-18. The R 0 represents the average number of secondary cases resulting from a single primary case in a totally susceptible population. This translates to a need to vaccinate about 93% of the population in order to disrupt measles transmission and achieve herd immunity. 7 Maintaining population

2019 Clinical Correlations

2. Proquad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

Proquad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf

2019 Health Canada - drugs and medical devices

3. Measles: post-exposure prophylaxis

Measles: post-exposure prophylaxis Measles: post-exposure prophylaxis - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Research and analysis Measles: post-exposure prophylaxis Guidelines on the use of post-exposure prophylaxis for measles in high-risk groups. Published 1 May 2009 Last updated 4 July 2019 — From: Documents Ref: PHE publications gateway number: GW-492 If you use assistive technology (...) (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This guidance summarises the evidence for the effectiveness of post-exposure prophylaxis ( 4 July 2019 Revised guidance. 17 June 2019 Updated guidelines on post-exposure prophylaxis for measles. 11 August 2017 Revised post-exposure prophylaxis guidance: details of changes on page 4. 1 May 2009 First

2019 Public Health England

4. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. (PubMed)

Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. The hypothesized link between the measles, mumps, rubella (MMR) vaccine and autism continues to cause concern and challenge vaccine uptake.To evaluate whether the MMR vaccine increases the risk for autism in children, subgroups of children, or time periods after vaccination.Nationwide cohort study.Denmark.657 461 children born in Denmark from 1999 through 31 December 2010, with follow-up from 1 year of age and through 31

Full Text available with Trip Pro

2019 Annals of Internal Medicine

5. Measles infection

Measles infection Measles infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Measles infection Last reviewed: February 2019 Last updated: March 2019 Summary Preventable by immunisation but high levels of coverage are required to prevent outbreaks of disease from occurring. No specific treatment for measles is available except for supportive care. Complications of measles are more common in immunocompromised (...) and poorly nourished individuals and include pneumonia, laryngotracheitis, otitis media, and encephalitis. Definition Measles is a highly infectious disease caused by measles virus, characterised by a maculopapular rash, cough, coryza, conjunctivitis, and a pathognomonic enanthem (Koplik's spots) with an incubation period of about 10 days. History and exam potential exposure to measles unimmunised or vaccine failure fever cough coryza conjunctivitis Koplik's spots maculopapular rash exposure to measles

2019 BMJ Best Practice

6. Dealing with a measles outbreak cost 20 times that of increasing vaccination cover

Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Discover Portal Discover Portal Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Published on 7 June 2016 doi: New research show that the total cost of the 2012-13 measles outbreak in Merseyside (£4.4 million) was more than twenty times the cost of the vaccinations that could have prevented (...) it (£182,909). The cost incorporated for the first time estimates of lost employment from having measles or looking after someone with it, and accounted for 44% (£2 million) of the total. Other costs included treatment of patients and public health costs, such as tracing and vaccinating people in contact with measles cases. Measles vaccinations work, but need to reach 95% or more of a group to prevent measles outbreaks in the population. If the proportion of vaccinated people in an area falls below

2019 NIHR Dissemination Centre

7. Measles outbreak investigation process in low- and middle-income countries (LMICs): a systematic review of the methods and costs of contact tracing

Measles outbreak investigation process in low- and middle-income countries (LMICs): a systematic review of the methods and costs of contact tracing Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

8. Vaccine effectiveness of two-dose vaccination with life attenuated measles containing vaccine: a systematic review and meta-analysis

Vaccine effectiveness of two-dose vaccination with life attenuated measles containing vaccine: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

9. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. (PubMed)

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Chikungunya fever is an emerging viral disease and substantial threat to public health. We aimed to assess the safety, tolerability, and immunogenicity of a live-attenuated, measles-vectored chikungunya vaccine (MV-CHIK).In this double-blind, randomised, placebo-controlled and active-controlled phase 2 trial, we (...) enrolled healthy volunteers aged 18-55 years at four study sites in Austria and Germany. Participants were randomly assigned to receive intramuscular injections with MV-CHIK (5 × 104 or 5 × 105 50% tissue culture infectious dose), control vaccine, or measles prime and MV-CHIK, in two different administration regimens. Randomisation was done by use of three-digit randomisation codes in envelopes provided by a data management service. The participants and investigators were masked to treatment assignment

2018 Lancet

10. Measles

Measles Top results for measles - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading (...) history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for measles The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

11. Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants

Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants Rotavirus vaccines given to infants are safe and efficacious. A booster dose of rotavirus vaccine could extend protection into the second year of life in low-resource countries.We conducted an open-label, individual-randomized trial in Bamako, Mali. We assigned 600 infants aged 9-11 months to receive measles vaccine (MV), yellow fever

Full Text available with Trip Pro

2018 EvidenceUpdates

12. Impact of measles supplementary immunisation activities on utilisation of maternal and child health services in low-income and middle-income countries (PubMed)

Impact of measles supplementary immunisation activities on utilisation of maternal and child health services in low-income and middle-income countries Measles supplementary immunisation activities (SIAs) are an integral component of measles elimination in low-income and middle-income countries (LMICs). Despite their success in increasing vaccination coverage, there are concerns about their negative consequences on routine services. Few studies have conducted quantitative assessments of SIA (...) not appear to significantly impact utilisation of maternal and child services. We find a reduction in care-seeking for treatment of child cough (OR 0.67; 95% CI 0.48 to 0.95); and a few significant effects at the country level, suggesting the need for further investigation of the idiosyncratic effects of SIAs in each country.The paper contributes to the debate on vertical versus horizontal programmes to ensure universal access to vaccination. Measles SIAs do not seem to affect care-seeking for critical

Full Text available with Trip Pro

2018 BMJ global health

13. Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study (PubMed)

Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study Beyond their impact on health, vaccines can lead to large economic benefits. While most economic evaluations of vaccines have focused on the health impact of vaccines at a national scale, it is critical to understand how their impact is distributed along population subgroups.We build a financial risk protection model (...) to evaluate the impact of immunisation against measles, severe pneumococcal disease and severe rotavirus for birth cohorts vaccinated over 2016-2030 for three scenarios in 41 Gavi-eligible countries: no immunisation, current immunisation coverage forecasts and the current immunisation coverage enhanced with funding support. We distribute modelled disease cases per socioeconomic group and derive the number of cases of: (1) catastrophic health costs (CHCs) and (2) medical impoverishment.In the absence

Full Text available with Trip Pro

2018 BMJ global health

14. Dealing with a measles outbreak cost 20 times that of increasing vaccination cover

Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Discover Portal Discover Portal Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Published on 7 June 2016 doi: New research show that the total cost of the 2012-13 measles outbreak in Merseyside (£4.4 million) was more than twenty times the cost of the vaccinations that could have prevented (...) it (£182,909). The cost incorporated for the first time estimates of lost employment from having measles or looking after someone with it, and accounted for 44% (£2 million) of the total. Other costs included treatment of patients and public health costs, such as tracing and vaccinating people in contact with measles cases. Measles vaccinations work, but need to reach 95% or more of a group to prevent measles outbreaks in the population. If the proportion of vaccinated people in an area falls below

2018 NIHR Dissemination Centre

15. Measles infection

Measles infection Measles infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Measles infection Last reviewed: February 2019 Last updated: March 2019 Summary Preventable by immunisation but high levels of coverage are required to prevent outbreaks of disease from occurring. No specific treatment for measles is available except for supportive care. Complications of measles are more common in immunocompromised (...) and poorly nourished individuals and include pneumonia, laryngotracheitis, otitis media, and encephalitis. Definition Measles is a highly infectious disease caused by measles virus, characterised by a maculopapular rash, cough, coryza, conjunctivitis, and a pathognomonic enanthem (Koplik's spots) with an incubation period of about 10 days. History and exam potential exposure to measles unimmunised or vaccine failure fever cough coryza conjunctivitis Koplik's spots maculopapular rash exposure to measles

2018 BMJ Best Practice

16. Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016

Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016 Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links (...) Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016 View/ Open View Statistics Altmetrics Share Citation World Health Organization = Organisation mondiale de la Santé . (‎2017)‎. Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016. Weekly Epidemiological Record = Relevé

2017 WHO

17. Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent (PubMed)

Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent Hematopoietic stem cell (HSC)-based gene therapy trials are now moving toward the use of lentiviral vectors (LVs) with success. However, one challenge in the field remains: efficient transduction of HSCs without compromising their stem cell potential. Here we showed that measles virus glycoprotein-displaying LVs (hemagglutinin and fusion protein LVs [H/F-LVs]) were capable

Full Text available with Trip Pro

2017 Blood advances

18. Incidence of Measles in the United States, 2001–2015 (PubMed)

Incidence of Measles in the United States, 2001–2015 28973240 2017 10 23 2018 11 13 1538-3598 318 13 2017 10 03 JAMA JAMA Incidence of Measles in the United States, 2001-2015. 1279-1281 10.1001/jama.2017.9984 Clemmons Nakia S NS Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia. Wallace Gregory S GS Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia. Patel Manisha M Division of Viral Diseases, US Centers (...) for Disease Control and Prevention, Atlanta, Georgia. Gastañaduy Paul A PA Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia. eng CC999999 Intramural CDC HHS United States Journal Article United States JAMA 7501160 0098-7484 0 Measles Vaccine AIM IM Adolescent Adult Aged Aged, 80 and over Child Child, Preschool Disease Outbreaks statistics & numerical data Humans Incidence Infant Measles epidemiology Measles Vaccine Middle Aged United States epidemiology Young

Full Text available with Trip Pro

2017 JAMA

19. Chickenpox and measles clusters among college students in Pune, Maharashtra (PubMed)

Chickenpox and measles clusters among college students in Pune, Maharashtra Chickenpox and measles, both vaccine preventable febrile rash illnesses, present in a comparatively severe form among young adults/adults than among children. Immunity levels against chickenpox are not known in India and those against measles have been found variable across the country. Places where students or adults/young adults from various parts of the country come together pose a peculiar challenge in preventive (...) policy making regarding these diseases. In this article, we present findings from parallel outbreaks of the two diseases in a graduate/postgraduate institute in the city of Pune. A team from National Institute of Virology [Pune] investigated outbreak of febrile rash illness in a premier graduate institute and found that it was a case of two parallel outbreaks of chickenpox and measles. In this outbreak chickenpox cases did not present with greater severity but measles cases were severe. The concerned

Full Text available with Trip Pro

2017 Virusdisease

20. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. (PubMed)

Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. Objectives To investigate whether measles, mumps, and rubella (MMR) vaccine has positive non-specific effects in a high income setting and to compare rates of hospital admissions for infections between children aged ≤2 years who received live MMR vaccine and those who received an inactivated vaccine against diphtheria, tetanus, pertussis, polio

Full Text available with Trip Pro

2017 BMJ